Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature

Autoimmunity Reviews

Volumn 12, Issue 2, 2012, Pages 127-136

  Antico, Antonio ^a   Tampoia, Marilina ^b   Tozzoli, Renato ^c   Bizzaro, Nicola ^d  

^a Ospedale Civile   (Italy)

^b Laboratorio di Patologia Clinica   (Italy)

^c S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^d Ospedale San Antonio   (Italy)

Author keywords

Autoimmune diseases; Autoimmunity; Hypovitaminosis D; Risk factors; Supplementation; Systematic review; Vitamin D level

Indexed keywords

VITAMIN D;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONNECTIVE TISSUE DISEASE; DENDRITIC CELL; DISEASE COURSE; DNA POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; TH1 CELL; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

AUTOIMMUNE DISEASES; DIETARY SUPPLEMENTS; ENVIRONMENT; GENE-ENVIRONMENT INTERACTION; GENETIC ASSOCIATION STUDIES; HUMANS; PREVALENCE; VITAMIN D;

EID: 84870244915     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.07.007     Document Type: Review

References (174)

1. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence?. Br J Nutr 2003, 89:552-572.
2. Selmi C. Autoimmunity in 2010. Autoimmun Rev 2011, 10:725-732.
3. Selmi C., Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 2010, 9:267-270.
4. Becker K.G. The common genetic hypothesis of autoimmune/inflammatory disease. Curr Opin Allergy Clin Immunol 2001, 1:399-405.
5. Sadovnick A.D. Genetic background of multiple sclerosis. Autoimmun Rev 2012, 11:163-166.
6. Costenbader K.H., Karlson E.W. Cigarette smoking and autoimmune disease: what can we learn from epidemiology?. Lupus 2006, 15:737-745.
7. Moroni L., Bianchi I., Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev 2012, 11:386-392.
8. accessed November 2008. http://www3.niaid.nih.gov/topics/autoimmune/PDF/ADCCFinal.pdf.
9. Sellner J., Kraus J., Awad A., Milo R., Hemmer B., Stüve O. The increasing incidence and prevalence of female multiple sclerosis - a critical analysis of potential environmental factors. Autoimmun Rev 2011, 10:495-502.
10. Cooper G.S., Stroehla B.C. The epidemiology of autoimmune diseases. Autoimmun Rev 2003, 2:119-125.
11. Souberbielle J.C., Body J.J., Lappe J.M., Plebani M., Shoenfeld Y., Wang T.J., et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010, 9:709-715.
12. Maruotti N., Cantatore F.P. Vitamin D and the immune system. J Rheumatol 2010, 37:491-495.
13. Alele J.D., Kamen D.L. The importance of inflammation and vitamin D status in SLE-associated osteoporosis. Autoimmun Rev 2010, 9:137-139.
14. Holick M.F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004, 79:362-371.
15. Cutolo M., Pizzorni C., Sulli A. Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev 2011, 11:84-87.
16. Arnson Y., Amital H., Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007, 66:1137-1142.
17. Peelen E., Knippenberg S., Muris A.H., Thewissen M., Smolders J., Tervaert J.W., et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev 2011, 10:733-743.
18. Gauzzi M.C., Purificato C., Donato K., Jin Y., Wang L., Daniel K.C., et al. Suppressive effect of 1alpha, 25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol 2005, 174:270-276.
19. +) T cells to enhance the development of Th2 cells. J Immunol 2001, 167:4974-4980.
20. van Etten E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005, 97:93-101.
21. Penna G., Amuchastegui S., Cossetti C., Aquilano F., Mariani R., Sanvito F., et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 2006, 177:8504-8511.
22. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007, 179:1634-1647.
23. Adorini L., Penna G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum Immunol 2009, 70:345-352.
24. Adorini L., Giarratana N., Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004, 16:127-134.
25. Penna G., Amuchastegui S., Giarratana N., Daniel K.C., Vulcano M., Sozzani S., et al. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 2007, 178:145-153.
26. Penna G., Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000, 164:2405-2411.
27. + regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005, 106:3490-3497.
28. Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 2005, 233:115-124.
29. Griffin M.D., Lutz W., Phan V.A., Bachman L.A., McKean D.J., Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001, 98:6800-6805.
30. Helming L., Bose J., Ehrchen J., Schiebe S., Frahm T., Geffers R., et al. 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 2005, 106:4351-4358.
31. Cantorna M.T., Mahon B.D. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004, 229:1136-1142.
32. Gregori S., Giarratana N., Smiroldo S., Uskokovic M., Adorini L. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002, 51:1367-1374.
33. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
34. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001, 106:263-266.
35. Cantorna M.T., Hayes C.E., DeLuca H.F. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998, 128:68-72.
36. Zella J.B., McCary L.C., DeLuca H.F. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys 2003, 417:77-80.
37. Cantorna M.T., Hayes C.E., DeLuca H.F. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996, 93:7861-7864.
38. Fournier C., Gepner P., Sadouk M., Charreire J. In vivo beneficial effects of cyclosporin A and 1,25-dihydroxyvitamin D3 on the induction of experimental autoimmune thyroiditis. Clin Immunol Immunopathol 1990, 54:53-63.
39. Daniel C., Radeke H.H., Sartory N.A., Zahn N., Zuegel U., Steinmeyer A., et al. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J Pharmacol Exp Ther 2006, 319:622-631.
40. Gysemans C.A., Cardozo A.K., Callewaert H., Giulietti A., Hulshagen L., Bouillon R., et al. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005, 146:1956-1964.
41. Pelajo C.F., Lopez-Benitez J.M., Miller L.C. Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev 2010, 9:507-510.
42. Marques C.D., Dantas A.T., Fragoso T.S., Duarte A.L. The importance of vitamin D levels in autoimmune diseases. Rev Bras Reumatol 2010, 50:67-80.
43. Kriegel M.A., Manson J.E., Costenbader K.H. Does vitamin D affect risk of developing autoimmune disease? A systematic review. Semin Arthritis Rheum 2011, 40:512-531.
44. Arteh J., Narra S., Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010, 55:2624-2628.
45. Roth H.J., Schmidt-Gayk H., Weber H., Niederau C. Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann Clin Biochem 2008, 45:153-159.
46. Kakalacheva K., Lünemann J.D. Environmental triggers of multiple sclerosis. FEBS Lett 2011, 585:3724-3729.
47. Stefanic M., Papic S., Suver M., Glavas-Obrovac L., Karner I. Association of vitamin D receptor gene 3[prime]-variants with Hashimoto's thyroiditis in the Croatian population. Int J Immunogenet 2008, 35:125-131.
48. Handunnetthi L., Ramagopalan S.V., Ebers G.C. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology 2010, 74:1905-1910.
49. Milo R., Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010, 9:387-394.
50. Disanto G., Ramagopalan S.V., Para A.E., Handunnetthi L. The emerging role of vitamin D binding protein in multiple sclerosis. J Neurol 2011, 258:353-358.
51. Simpson S., Blizzard L., Otahal P., Van der Mei I., Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011, 82:1132-1141.
52. Ponsonby A.L., McMichael A., van der Mei I. Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology 2002, 181-182:71-78.
53. Sonnenberg A., Wasserman I.H. Epidemiology of inflammatory bowel disease among U.S. military veterans. Gastroenterology 1991, 101:122-130.
54. Cantorna M.T. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol 2006, 92:60-64.
55. Hernan M.A., Olek M.J., Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999, 53:1711-1718.
56. Staples J.A., Ponsonby A.L., Lim L.L., McMichael A.J. Ecologic analysis of some immune-related disorders, including type 1 diabetes, in Australia: latitude, regional ultraviolet radiation, and disease prevalence. Environ Health Perspect 2003, 111:518-523.
57. Handel A.E., Handunnetthi L., Giovannoni G., Ebers G.C., Ramagopalan S.V. Genetic and environmental factors and the distribution of multiple sclerosis in Europe. Eur J Neurol 2010, 17:1210-1214.
58. Vieira V.M., Hart J.E., Webster T.F., Weinberg J., Puett R., Laden F., et al. Association between residences in U.S. northern latitudes and rheumatoid arthritis: a spatial analysis of the Nurses' Health Study. Environ Health Perspect 2010, 118:957-961.
59. Ascherio A., Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 2008, 28:17-28.
60. Salzer J., Svenningsson A., Sundström P. Season of birth and multiple sclerosis in Sweden. Acta Neurol Scand 2010, 122:70-73.
61. Auer D.P., Schumann E.M., Kumpfel T., Gossl C., Trenkwalder C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000, 47:276-277.
62. Borkar V.V., Devidayal, Verma S., Bhalla A.K. Low levels of vitamin D in North Indian children with newly diagnosed type 1 diabetes. Pediatr Diabetes 2010, 11:345-350.
63. Singh D.K., Winocour P., Summerhayes B., Viljoen A., Sivakumar G., Farrington K. Are low erythropoietin and 1,25-dihydroxyvitamin D levels indicative of tubulo-interstitial dysfunction in diabetes without persistent microalbuminuria?. Diabetes Res Clin Pract 2009, 85:258-264.
64. Bener A., Alsaied A., Al-Ali M., Al-Kubaisi A., Basha B., Abraham A., et al. High prevalence of vitamin D deficiency in type 1 diabetes mellitus and healthy children. Acta Diabetol 2009, 46:183-189.
65. Greer R.M., Rogers M.A., Bowling F.G., Buntain H.M., Harris M., Leong G.M., et al. Australian children and adolescents with type 1diabetes have low vitamin D levels. Med J Aust 2007, 187:59-60.
66. Littorin B., Blom P., Scholin A., Arnqvist H.J., Blohme G., Bolinder J., et al. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 2006, 49:2847-2852.
67. Verrotti A., Basciani F., Carle F., Morgese G., Chiarelli F. Calcium metabolism in adolescents and young adults with type 1 diabetes mellitus without and with persistent microalbuminuria. J Endocrinol Invest 1999, 22:198-202.
68. Baumgartl H.J., Standl E., Schmidt-Gayk H., Kolb H.J., Janka H.U., Ziegler A.G. Changes of vitamin D3 serum concentrations at the onset of immune-mediated type 1 (insulin-dependent) diabetes mellitus. Diabetes Res 1991, 16:145-148.
69. Rodland O., Markestad T., Aksnes L., Aarskog D. Plasma concentrations of vitamin D metabolites during puberty of diabetic children. Diabetologia 1985, 28:663-666.
70. Huynh T., Greer R.M., Nyunt O., Bowling F., Cowley D., Leong G.M., et al. The association between ketoacidosis and 25(OH)-vitamin D levels at presentation in children with type 1 diabetes mellitus. Pediatr Diabetes 2009, 10:38-43.
71. Di Cesar D.J., Ploutz-Snyder R., Weinstock R.S., Moses A.M. Vitamin D deficiency is more common in type 2 than in type 1 diabetes. Diabetes Care 2006, 29:174.
72. Bierschenk L., Alexander J., Wasserfall C., Haller M., Schatz D., Atkinson M. Vitamin D levels in subjects with and without type 1 diabetes residing in a solar rich environment. Diabetes Care 2009, 32:1977-1979.
73. Holmoy T., Moen S.M., Gundersen T.A., Holick M.F., Fainardi E., Castellazzi M., et al. 25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult Scler 2009, 15:1280-1285.
74. Hiremath G.S., Cettomai D., Baynes M., Ratchford J.N., Newsome S., Harrison D., et al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 2009, 15:735-740.
75. Correale J., Ysrraelit M.C., Gaitan M.I. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009, 132:1146-1160.
76. Kragt J., van Amerongen B., Killestein J., Dijkstra C., Uitdehaag B., Polman C., et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 2009, 15:9-15.
77. Soilu-Hanninen M., Airas L., Mononen I., Heikkila A., Viljanen M., Hanninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005, 11:266-271.
78. Smolders J., Menheere P., Kessels A., Damoiseaux J., Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008, 14:1220-1224.
79. van der Mei I.A., Ponsonby A.L., Dwyer T., Blizzard L., Taylor B.V., Kilpatrick T., et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007, 254:581-590.
80. Soilu-Hänninen M., Laaksonen M., Laitinen I., Erälinna J.P., Lilius E.M., Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008, 79:152-157.
81. Embry A.F., Snowdon L.R., Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000, 48:271-272.
82. Barnes M.S., Bonham M.P., Robson P.J., Strain J.J., Lowe-Strong A.S., Eaton-Evans J., et al. Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Mult Scler 2007, 13:670-672.
83. Orton S.M., Morris A.P., Herrera B.M., Ramagopalan S.V., Lincoln M.R., Chao M.J., et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 2008, 88:441-447.
84. Vogt M.H., ten Kate J., Drent R.J., Polman C.H., Hupperts R. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult Scler 2010, 16:443-449.
85. 3 in patients with systemic lupus erythematosus. Pol Merkur Lekarski 2010, 28:103-107.
86. Kim H.A., Sung J.M., Jeon J.Y., Yoon J.M., Suh C.H. Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus. Rheumatol Int 2011, 31:1189-1194.
87. Damanhouri L.H. Vitamin D deficiency in Saudi patients with systemic lupus erythematosus. Saudi Med J 2009, 30:1291-1295.
88. Wright T.B., Shults J., Leonard M.B., Zemel B.S., Burnham J.M. Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J Pediatr 2009, 155:260-265.
89. Borba V.Z., Vieira J.G., Kasamatsu T., Radominski S.C., Sato E.I., Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 2009, 20:427-433.
90. Muller K., Kriegbaum N.J., Baslund B., Sorensen O.H., Thymann M., Bentzen K. Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 1995, 14:397-400.
91. Cutolo M., Otsa K., Uprus M., Paolino S., Seriolo B. Vitamin D in rheumatoid arthritis. Autoimmun Rev 2007, 7:59-64.
92. Als O.S., Riis B., Christiansen C. Serum concentration of vitamin D metabolites in rheumatoid arthritis. Clin Rheumatol 1987, 6:238-243.
93. Turhanoglu A.D., Güler H., Yönden Z., Aslan F., Mansuroglu A., Ozer C. The relationship between vitamin D and disease activity and functional health status in rheumatoid arthritis. Rheumatol Int 2011, 31:911-914.
94. Braun-Moscovici Y., Toledano K., Markovits D., Rozin A., Nahir A.M., Balbir-Gurman A. Vitamin D level: is it related to disease activity in inflammatory joint disease?. Rheumatol Int 2011, 3:493-499.
95. Feser M., Derber L.A., Deane K.D., Lezotte D.C., Weisman M.H., Buckner J.H., et al. Plasma 25, OH vitamin D concentrations are not associated with rheumatoid arthritis (RA)-related autoantibodies in individuals at elevated risk for RA. J Rheumatol 2009, 36:943-946.
96. Bird H.A., Wright V., Hennes U., Theiss E. Comparison of serum 1,25-dihydroxycholecalciferol concentrations in rheumatoid arthritis and osteoarthrosis. Ann Rheum Dis 1982, 4:257-258.
97. Shinjo S.K., Bonfá E., de Falco Caparbo V., Pereira R.M. Low bone mass in juvenile onset sclerosis systemic: the possible role for 25-hydroxyvitamin D insufficiency. Rheumatol Int 2011, 31:1075-1080.
98. Calzolari G., Data V., Carignola R., Angeli A. Hypovitaminosis D in systemic sclerosis. J Rheumatol 2009, 36:2844. author reply 2845.
99. Braun-Moscovici Y., Furst D.E., Markovits D., Rozin A., Clements P.J., Nahir A.M., et al. Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosis. J Rheumatol 2008, 35:2201-2205.
100. Matsuoka L.Y., Dannenberg M.J., Wortsman J., Hollis B.W., Jimenez S.A., Varga J. Cutaneous vitamin D3 formation in progressive systemic sclerosis. J Rheumatol 1991, 18:1196-1198.
101. Serup J., Hagdrup H. Vitamin D metabolites in generalized scleroderma. Evidence of a normal cutaneous and intestinal supply with vitamin D. Acta Derm Venereol 1985, 65:343-345.
102. Serup J., Hagdrup H.K. Increased 1,25-dihydroxyvitamin D in patients with generalized scleroderma and no aberrant calcifications. Arch Dermatol Res 1984, 276:205-206.
103. Rios Fernández R., Fernández Roldán C., Callejas Rubio J.L., Ortego Centeno N. Vitamin D deficiency in a cohort of patients with systemic scleroderma from the south of Spain. J Rheumatol 2010, 37:1355.
104. Cutolo M., Otsa K., Laas K., Yprus M., Lehtme R., Secchi M.E., et al. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol 2006, 24:702-704.
105. Looker A.C., Dawson-Hughes B., Calvo M.S., Gunter E.W., Sahyoun N.R. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002, 30:771-777.
106. Ginde A.A., Mansbach J.M., Camargo C.A. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009, 169:384-390.
107. Kumar J., Muntner P., Kaskel F.J., Hailpern S.M., Melamed M.L. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics 2009, 124:e362-e370.
108. Antico A., Tozzoli R., Giavarina D., Tonutti E., Bizzaro N. Hypovitaminosis D as predisposing factor for atrophic type A gastritis: a case-control study and review of the literature on the interaction of vitamin D with the immune system. Clin Rev Allergy Immunol 2011, 42:355-364.
109. Cutillas-Marco E., Morales-Suárez-Varela M., Marquina-Vila A., Grant W. Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus 2010, 19:810-814.
110. Sedrani S.H. Low 25-hydroxyvitamin D and normal serum calcium concentrations in Saudi Arabia: Riyadh region. Ann Nutr Metab 1984, 28:181-185.
111. El-Hajj Fuleihan G., Nabulsi M., Choucair M., Salamoun M., Hajj Shahine C., Kizirian A., et al. Hypovitaminosis D in healthy schoolchildren. Pediatrics 2001, 107:E53.
112. Mansoor S., Habib A., Ghani F., Fatmi Z., Badruddin S., Mansoor S., et al. Prevalence and significance of vitamin D deficiency and insufficiency among apparently healthy adults. Clin Biochem 2010, 43:1431-1435.
113. Gordon C.M., DePeter K.C., Feldman H.A., Grace E., Emans S.J. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004, 158:531-537.
114. Sullivan S.S., Rosen C.J., Halteman W.A., Chen T.C., Holick M.F. Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet Assoc 2005, 105:971-974.
115. Lips P. Vitamin D deficiency in a multicultural setting. Ned Tijdschr Geneeskd 2001, 145:2060-2062. [Dutch].
116. Puri S., Marwaha R.K., Agarwal N., Tandon N., Agarwal R., Grewal K., et al. Vitamin D status of apparently healthy schoolgirls from two different socioeconomic strata in Delhi: relation to nutrition and lifestyle. Br J Nutr 2008, 99:876-882.
117. Nesby-O'Dell S., Scanlon K.S., Cogswell M.E., Gillespie C., Hollis B.W., Looker A.C., et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2002, 76:187-192.
118. Looker A.C., Pfeiffer C.M., Lacher D.A., Schleicher R.L., Picciano M.F., Yetley E.A. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008, 88:1519-1527.
119. Amital H., Szekanecz Z., Szücs G., Dankó K., Nagy E., Csépány T., et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?. Ann Rheum Dis 2010, 69:1155-1157.
120. Ben-Zvi I., Aranow C., Mackay M., Stanevsky A., Kamen D.L., Marinescu L.M., et al. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS One 2010, 5:e9193.
121. Wu P.W., Rhew E.Y., Dyer A.R., Dunlop D.D., Langman C.B., Price H., et al. 25-Hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum 2009, 61:1387-1395.
122. Thudi A., Yin S., Wandstrat A.E., Li Q.Z., Olsen N.J. Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am J Med Sci 2008, 335:99-104.
123. Huisman A.M., White K.P., Algra A., Harth M., Vieth R., Jacobs J.W., et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 2001, 28:2535-2539.
124. Ruiz-Irastorza G., Egurbide M.V., Olivares N., Martinez-Berriotxoa A., Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008, 47:920-923.
125. Toloza S.M., Cole D.E., Gladman D.D., Ibanez D., Urowitz M.B. Vitamin D insufficiency in a large female SLE cohort. Lupus 2010, 19:13-19.
126. Broder A.R., Tobin J.N., Putterman C. Disease-specific definitions of vitamin D deficiency need to be established in autoimmune and non-autoimmune chronic diseases: a retrospective comparison of three chronic diseases. Arthritis Res Ther 2010, 12:R191.
127. Kamen D.L., Cooper G.S., Bouali H., Shaftman S.R., Hollis B.W., Gilkeson G.S. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006, 5:114-117.
128. Patel S., Farragher T., Berry J., Bunn D., Silman A., Symmons D. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 2007, 56:2143-2149.
129. Oelzner P., Müller A., Deschner F., Hüller M., Abendroth K., Hein G., et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998, 62:193-198.
130. Kroger H., Penttila I.M., Alhava E.M. Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand J Rheumatol 1993, 22:172-177.
131. Craig S.M., Yu F., Curtis J.R., Alarcon G.S., Conn D.L., Jonas B., et al. Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. J Rheumatol 2010, 37:275-281.
132. Caramaschi P., Dalla Gassa A., Ruzzenente O., Volpe A., Ravagnani V., Tinazzi I., et al. Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 2010, 29:1419-1425.
133. Vacca A., Cormier C., Piras M., Mathieu A., Kahan A., Allanore Y. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol 2009, 36:1924-1929.
134. Svoren B.M., Volkening L.K., Wood J.R., Laffel L.M. Significant vitamin D deficiency in youth with type 1 diabetes mellitus. J Pediatr 2009, 154:132-134.
135. Arreola F., Paniagua R., Diaz-Bensussen S., Urquieta B., Lopez-Montano E., Partida Hernandez G., et al. Bone mineral content, 25-hydroxycalciferol and zinc serum levels in insulin-dependent (type I) diabetic patients. Arch Invest Med (Mex) 1990, 21:195-199.
136. Storm T.L., Sorensen O.H., Lund B., Christiansen J.S., Andersen A.R., Lumholtz I.B., et al. Vitamin D metabolism in insulin-dependent diabetes mellitus. Metab Bone Dis Relat Res 1983, 5:107-110.
137. Mathieu C., Waer M., Laureys J., Rutgeerts O., Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994, 37:552-558.
138. Mathieu C., Waer M., Casteels K., Laureys J., Bouillon R. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology 1995, 136:866-872.
139. Casteels K.M., Mathieu C., Waer M., Valckx D., Overbergh L., Laureys J.M., et al. Prevention of type I diabetes in nonobese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D3 in combination with a short induction course of cyclosporin A. Endocrinology 1998, 139:95-102.
140. Lemire J.M., Archer D.C., Reddy G.S. 1,25-Dihydroxy-24-OXO-16ene-vitamin D3, a renal metabolite of the vitamin D analog 1,25-dihydroxy-16ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. Endocrinology 1994, 135:2818-2821.
141. Cantorna M.T., Woodward W.D., Hayes C.E., DeLuca H.F. 1,25-Dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol 1998, 160:5314-5319.
142. Tetlow L.C., Woolley D.E. The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res 1999, 1:63-70.
143. Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate?. J Steroid Biochem Mol Biol 2004, 89-90:611-614.
144. Ruiz-Irastorza G., Gordo S., Olivares N., Egurbide M.V., Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity and damage. Arthritis Care Res (Hoboken) 2010, 62:1160-1165.
145. Andjelkovic Z., Vojinovic J., Pejnovic N., Popovic M., Dujic A., Mitrovic D., et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999, 17:453-456.
146. Brohult J., Jonson B. Effects of large doses of calciferol on patients with rheumatoid arthritis. A double-blind clinical trial. Scand J Rheumatol 1973, 2:173-176.
147. Achiron A., Barak Y., Miron S., Izhak Y., Faibel M., Edelstein S. Alfacalcidol treatment in multiple sclerosis. Clin Neuropharmacol 2003, 26:53.
148. Goldberg P., Fleming M.C., Picard E.H. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986, 2:193-200.
149. Caca-Biljanovska N.G., Vlckova-Laskoska M.T., Dervendi D.V., Pesic N.P., Laskoski D.S. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol 1999, 455:299-304.
150. Elst E.F., Van Suijlekom-Smit L.W., Oranje A.P. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol 1999, 16:53-58.
151. Hulshof M.M., Bouwes Bavinck J.N., Bergman W., Masclee A.A., Heickendorff L., Breedveld F.C., et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000, 43:1017-1023.
152. Humbert P., Dupond J.L., Agache P., Laurent R., Rochefort A., Drobacheff C., et al. Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol 1993, 73:449-451.
153. Wingerchuk D.M., Lesaux J., Rice G.P., Kremenchutzky M., Ebers G.C. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005, 76:1294-1296.
154. Burton J.M., Kimball S., Vieth R., Bar-Or A., Dosch H.M., Cheung R., et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74:1852-1859. Erratum in: Neurology 2010; 75:480.
155. Li X., Liao L., Yan X., Huang G., Lin J., Lei M., et al. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2009, 25:411-416.
156. Pitocco D., Crino A., Di Stasio E., Manfrini S., Guglielmi C., Spera S., et al. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med 2006, 23:920-923.
157. Arnson Y., Amital H., Agmon-Levin N., Alon D., Sánchez-Castañón M., López-Hoyos M., et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev 2011, 10:490-494.
158. Zold E., Szodoray P., Nakken B., Barath S., Kappelmayer J., Csathy L., et al. Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease. Autoimmun Rev 2011, 10:155-162.
159. Doria A., Zen M., Canova M., Bettio S., Bassi N., Nalotto L., et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010, 10:55-60.
160. Nielen M.M., van Schaardenburg D., Lems W.F., van de Stadt R.J., de Koning M.H., Reesink H.W., et al. Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al. Arthritis Rheum 2006, 54:3719-3720.
161. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
162. Tenconi M.T., Devoti G., Comelli M., Pinon M., Capocchiano A., Calcaterra V., et al. Major childhood infectious diseases and other determinants associated with type 1 diabetes: a case-control study. Acta Diabetol 2007, 44:14-19.
163. Stene L.C., Joner G. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 2003, 78:1128-1134.
164. Stene L.C., Ulriksen J., Magnus P., Joner G. Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia 2000, 43:1093-1098.
165. The E.U.R.O.D.I.A.B. Substudy 2 Study Group. Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. Diabetologia 1999, 42:51-54.
166. Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008, 93:512-517.
167. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503.
168. Fronczak C.M., Baron A.E., Chase H.P., Ross C., Brady H.L., Hoffman M., et al. In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care 2003, 26:3237-3242.
169. Marjamaki L., Niinisto S., Kenward M.G., Uusitalo L., Uusitalo U., Ovaskainen M.L., et al. Maternal intake of vitamin D during pregnancy and risk of advanced beta cell autoimmunity and type 1 diabetes in offspring. Diabetologia 2010, 53:1599-1607.
170. Brekke H.K., Ludvigsson J. Vitamin D supplementation and diabetes-related autoimmunity in the ABIS study. Pediatr Diabetes 2007, 8:11-14.
171. Merlino L.A., Curtis J., Mikuls T.R., Cerhan J.R., Criswell L.A., Saag K.G. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004, 50:72-77.
172. Costenbader K.H., Feskanich D., Holmes M., Karlson E.W., Benito-Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis 2008, 67:530-535.
173. Munger K.L., Zhang S.M., O'Reilly E., Hernan M.A., Olek M.J., Willett W.C., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
174. Vieth R. Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol 2004, 89-90:575-579.